Tazorac is a prescription-only skin-care medication marketed in Hong Kong by the Department of Health. It contains the active ingredient tazarotene, a synthetic retinoid that modifies skin cell growth. Tazorac is supplied in a tube formulation with strengths of 1 % and 5 % tazarotene.
Tazarotene is a selective agonist of retinoic acid receptors (RAR-β and RAR-γ) in the skin. By binding to these receptors, it:
The therapeutic effect typically begins within a few weeks of consistent use, with peak results appearing after several months.
In Hong Kong, Tazorac is approved by the Department of Health for the following indications:
These uses are based on clinical trials that demonstrated reduction in inflammatory lesions and plaque thickness when applied as directed.
No well-established off-label uses for Tazorac have been identified in peer-reviewed guidelines. If clinicians consider alternative applications, they must do so under strict medical supervision and document the rationale.
Absolute contraindications
Relative contraindications
Special populations such as pregnant or lactating women should avoid Tazorac entirely. For elderly patients, skin fragility may increase the risk of irritation; gentle application is advised.
These effects are usually mild to moderate and tend to lessen with continued use or the addition of moisturizers.
If any of these serious reactions develop, the medication should be stopped and medical care sought promptly.
This article provides educational information about Tazorac and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Tazorac is commonly prescribed for facial acne and for plaque psoriasis on the scalp, trunk, or limbs. Application sites should be discussed with a dermatologist to ensure appropriate use and to minimize irritation.
The 5 % formulation contains a higher concentration of tazarotene, which may be selected for more severe or resistant skin conditions. The 1 % tube is typically used for milder disease or for patients who are more prone to irritation.
Visible reduction in acne lesions usually begins after 4-6 weeks of consistent use, though optimal results may require 12 weeks or longer.
Concurrent use of other topical retinoids, benzoyl peroxide, or strong exfoliants can increase irritation. It is advisable to introduce additional products gradually and under professional supervision.
Yes. Tazarotene can increase skin sensitivity to sunlight. Broad-spectrum sunscreen with SPF 30 or higher should be applied each morning.
No. Tazarotene is teratogenic and should be avoided by women who are pregnant, planning pregnancy, or breastfeeding.
Stop using the product, gently cleanse the area with lukewarm water, apply a bland moisturizer, and seek medical advice promptly.
Tazarotene is marketed under the brand name Tazorac in Hong Kong. Generic equivalents may be available, but exact formulations and strengths should be confirmed with a pharmacist.
Keep the tube in a cool, dry place away from direct sunlight. If traveling by air, place the tube in a carry-on bag to avoid temperature extremes in cargo holds.
Long-term use may lead to mild hypopigmentation or hyperpigmentation in some individuals, especially if excessive sun exposure occurs. Monitoring skin tone changes with a dermatologist is recommended.
